BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 11, 2025
See today's BioWorld
Home
» Regulatory actions for June 21, 2023
To read the full story,
subscribe
or
sign in
.
Regulatory actions for June 21, 2023
June 21, 2023
No Comments
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aardvark, Advantage, Agepha, Akebia, Aldeyra, Amarin, Amgen, Arcellx, Argenx, Aridis, ARS, Biologix, Boehringer Ingelheim, Geron, Pfizer, Precigen, Replay, Sonnet.
BioWorld
Briefs
Regulatory
Regulatory actions